Pseudomonas aeruginosa est un pathogène opportuniste induisant des infections chroniques chez les patients atteints de mucoviscidose. L'éradication de ces infections est presque impossible à l'âge adulte du fait de la formation de biofilms dans les poumons des patients. Les traitements antibiotiques actuels sont peu efficaces contre les biofilms car ce mode de vie assure d'une part la protection des bactéries contre les agents anti-microbiens par l'intermédiaire de la matrice extracellulaire, et favorise d'autre part l'émergence de mécanismes de résistance. Il est donc essentiel de trouver des alternatives thérapeutiques. La bactérie marine Pseudoalteromonas sp. 3J6 sécrète une molécule à activité anti-biofilm efficace contre la souche de laboratoire P. aeruginosa PA01 et les souches cliniques P. aeruginosa MUC-N1, MUC-N2 et MUC-P4. Ces souches ont été caractérisées aux niveaux de leur formation de biofilms in vitro et de leur virulence . Ceci a montré que ces souches sont très différentes les unes des autres et qu'une seule souche, telle que la souche de laboratoire PA01, ne peut pas être représentative des profils observés. Il est donc nécessaire de mener les études anti-biofilms sur plusieurs souches, telles que celles que nous avons sélectionnées. Le potentiel thérapeutique du surnageant de culture (SNa.Js} de Pseudoalteromonas sp. 3J6 et son extrait (Ea.Js} a été étudié en évaluant leur toxicité, la réponse inflammatoire, leur impact sur la production de facteurs de virulence et leur potentiel thérapeutique . SNa.Js et Ea.Js n'étaient pas toxiques vis-à-vis des modèles testés, n'induisaient pas de réponse inflammatoire dans les poumons de souris et n'augmentaient pas la production par P. aeruginosa des facteurs de virulence quantifiés. De plus, SNa.Js s'est avèré être aussi efficace que l'antibiotique ciprofloxacine pour traiter une infection à P. aeruginosa MUC-N2 in vivo sur modèle murin. Ces résultats sont encourageants quant à un potentiel thérapeutique de la molécule à activité anti-biofilm pour contribuer au traitement des infections à P. aeruginosa chez les patients atteints de mucoviscidose. / Pseudomonas aeruginosa is an opportunistic pathogen leading to chronic infections in patients suffering of cystic fibrosis. Eradication of these infections is almost impossible in adults because of biofilm formation in patient's lungs. Current antibiotics treatments are not efficient enough against biofilms because this lifestyle first protects bacteria from antimicrobial agents via the biofilm extracellular matrix and secondly promotes the emergence of antibiotic resistance mechanisms. lt is therefore essential to find therapeutic alternatives . The marine bacterium Pseudoalteromonas sp. 3J6 secretes an anti-biofilm molecule active against the laboratory P. aeruginosa PA01 strain and the P. aeruginosa clinical strains MUC-N1, MUC-N2 and MUC­ P4. These strains were characterized at the levels of in vitro biofilm formation, and of their virulence. This part of the research work highlighted that these strains are different from one to another and that a single strain, such as the laboratory strain PA01, cannot be representative of the various patterns. Anti-biofilm studies have thus to be performed on several strains, such as the ones we selected. The therapeutic potential of the culture supernatant (SNa.Js} of Pseudoalteromonas sp. 3J6 and its extract Ea.Js was studied by evaluating their toxicity, inflammatory response, impact on virulence factors production, and therapeutic efficiency. SNa.Js and Ea.Js were not taxie against the tested models; did not induce inflammatory response in mice lungs, and did not enhance virulence factor production by clinical P. aerugonisa strains. Moreover, SNa.Js was as efficient as the ciprofloxacin antibiotic to treat an in vivo infection by P. aeruginosa MUC-N2 on mice. These results are encouraging as for a therapeutic potential of the anti-biofilm molecule to contribute at the treatment of P. aeruginosa infections of cystic fibrosis patients.

CoordenaÃÃo de AperfeiÃoamento de Pessoal de NÃvel Superior / Este trabalho descreve o estudo quÃmico e biolÃgico dos extratos das bactÃrias marinhas Pseudoalteromonas sp., Micromonospora sp., Streptomyces sp. e Kocuria sp., visando o isolamento e a elucidaÃÃo estrutural de novos constituintes bioativos. A investigaÃÃo quÃmica realizada com a bactÃria Pseudoalteromonas sp. resultou no isolamento de um pigmento vermelho identificado como prodigiosina e de dois Ãcidos biliares conhecidos como Ãcido desoxicÃlico e Ãcido cÃlico. A prodigiosina foi testada frente a quatro linhagens de cÃlulas tumorais e apresentou valores de IC50 semelhantes ao padrÃo positivo. O estudo quÃmico de Micromonospora sp. resultou no isolamento de quatro novas antraciclinonas: 4,6,11-triidroxi-9-propriltetraceno-5,12-diona; 4-metoxi-9-propiltetraceno-6,11-diona; 7,8,9,10-tetraidro-9-hidroxi-4-metoxi-9-propiltetra-ceno-6,11-diona e 10β-metoxicarbonil-7,8,9,10-tetraidro-4,6,7α,9α,11âpentaidroxiâ9âpropil-tetraceno-5,12-diona. Esses compostos foram avaliados quanto a sua atividade anti-tumoral frente a linhagem celular HCT-8, dois dos quais mostraram citotoxidade moderada com valores de IC50 de 12,74 e 6,18 M. O estudo da bactÃria Streptomyces sp. possibilitou o isolamento de uma ditiolpirrolidina cuja estrutura foi estabelecida como 5-oxo-6-(N-metilformamida)-4,5- diidro-1,2-ditiol[4,3-b]pirrol. Esse metabÃlito teve sua atividade citotÃxica testada frente a seis linhagens celulares tumorais, mostrando forte atividade com IC50 de 1,66, 1,05 e 1,52 ÂM para as linhagens de prÃstata metastÃtica, carcinoma de ovÃrio e glioblastoma, respectivamente. O estudo de Kocuria sp. resultou no isolamento de um novo peptÃdeo denominado como kocurina. Esse composto teve sua atividade antimicrobiana testada frente a vÃrias bactÃrias e fungos patogÃnicos, incluindo cepas de Staphylococcus aureus resistentes a meticilina (MRSA) e cepas de Staphylococcus aureus resistentes a tiazomicina. Kocurina inibiu fortemente o crescimento de MRSA MB5393 com valores de CIM de 0,25Âg/mL, alÃm de exibir atividade antibacteriana contra as bactÃrias Bacillus subtilis e Enterococcus faecium. As estruturas de todos os compostos isolados neste trabalho foram determinadas empregando mÃtodos espectroscÃpicos tais como RMN 1H e 13C (1D e 2D), espectrometria de massas e infravermelho. / This work describe the chemical and biological investigation of the extracts from the marine bacterias Pseudoalteromonas sp., Micromonospora sp., Streptomyces sp. and Kocuria sp., aiming the isolation and structural elucidation of new bioactive constituents. The chemical investigation carried out with the bacteria Pseudoalteromonas sp. lead to the isolation a red pigment identified as prodigiosin and two bile acids derivatives known as deoxycholic acid and cholic acid. The prodigiosin was evaluated against four tumor cell lines showing IC50 values similar to the positive control doxorubicin. The chemical study of Micromonospora sp. Resulted in the isolation of four new anthracyclinones designed as 4,6,11-trihydroxy-9-propryltetracene-5,12-dione; 4-methoxy-9-propyltetracene-6,11-dione; 7,8,9,10 - tetrahydro-9-hydroxy-4-methoxy-9-propiltetra-cene-6,11-dione and 10β-Carbomethoxy-7,8,9,10-tetrahydro-4,6,7α,9α,11-pentahydroxy-9-propyltetracene-5,12-dione . The cytotoxic potential of these compounds were evaluated against HCT-8cell line, two of which showed moderate cytotoxicity with IC50 values of 12.74 and 6.18 M, respectively. From Streptomyces sp. strain was isolated a ditiolpyrrolidin, established as 5-oxo-6-(N-methylformamide) -4,5 - dihydro-1,2-dithiol [4,3-b] pyrrole. This secondary metabolite was tested against six tumor cell lines, shown IC50 values of 1.66, 1.05 and 1.52 mM for the metastatic prostate lines, ovarium carcinoma and glioblastoma, respectively. The study of Kocuria sp. lead to the isolation of a new peptide, which was designed as kocurin. This compound was subjected to the tested its antimicrobial assays against several pathogens bacteria and fungal including Staphylococcus aureus strains methicillin resistant (MRSA) and Staphylococcus aureus strains tiazomicin resistant. Kocurin was strongly active against MRSA MB5393 exhibiting a MIC of 0,25Âg/mL, moreover showed antibacterial activity against Bacillus subtilis and Enterococcus faecium. The structures of all isolated compounds in this work were stabilized employing spectroscopic methods such as 1H and 13C NMR (1D and 2D), mass spectrometry and infrared.